Objective response rate

Nearly all patients achieved a response (n=52/60) and 62% of patients achieved CR with TECARTUS at a median study follow-up of 12.3 months1,2

Objective response rate graph Objective response rate graph

Pinch to zoom

Responses were rapid—the median time to initial response was 1 month (range: 0.8-3.1 months)1,3

  • Median time to complete response was 3 months (range: 1.0-9.3 months)

Many responses deepened over time3

  • 76% (n=28/37) of patients who achieved CR converted from PR or stable disease
    • Of the 76% of patients who converted to CR, most (n=25/28) converted from PR
    • Conversions occurred as late as 8.3 months postinfusion

Consistent response rates demonstrated across efficacy analyses1

Response Rates in ZUMA-2. Response Rates in ZUMA-2.

*Among all responders. DOR is measured from the date of first objective response to the date of progression or death.1

CI=confidence interval; CR=complete response; DOR=duration of response; ITT=intent-to-treat; MCL=mantle cell lymphoma; NE=not estimable; NR=not reached; OR=objective response; ORR=objective response rate; PR=partial response; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file [1]. Kite Pharma, Inc; 2020. 3. Data on file [2]. Kite Pharma, Inc; 2020.

Duration of response

With TECARTUS, median duration of response was not reached at a median study follow-up of 12.3 months1-3*

  • DOR was a secondary endpoint of the ZUMA-2 phase 2, single-arm, open-label study
  • DOR data below are descriptive and should be carefully interpreted in light of the single-arm design
Duration of Response graph Duration of Response graph

Pinch to zoom

  • 62% (n=32/52) of all patients who responded and 81% (n=30/37) of patients with a CR remained in remission at the time of analysis1,3
    • Median duration of follow-up for DOR in all responders was 8.6 months (range: 7.9-20.9 months) and in patients with a CR was 8.5 months (range: 7.8-20.9 months)3

Long-term follow-up

  • In the patients with ≥2 years follow-up, 43% (n=12/28) had an ongoing response3

Duration of response was consistent across efficacy analyses1

Duration of Response in ZUMA-2. Duration of Response in ZUMA-2.

*Kaplan-Meier estimate based on the 52 patients with a response.3

A + sign indicates a censored value.

BTKi=Bruton's tyrosine kinase inhibitor; CI=confidence interval; CR=complete response; DOR=duration of response; ITT=intent-to-treat; MCL=mantle cell lymphoma; NE=not estimable; NR=not reached; OR=objective response; ORR=objective response rate; PR=partial response; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file [1]. Kite Pharma, Inc; 2020. 3. Data on file [2]. Kite Pharma, Inc; 2020.